Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ensuring Leading Position For GSK Consumer Products Touted In Management Shift

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.

You may also be interested in...



Glaxo Launches Flonase OTC, Banks On More Consumer Growth Drivers

CEO Andrew Witty says the consumer business GSK is forming through brand divestitures and its JV with Novartis is a part of “the company I've been trying to create for seven years.” GSK’s OTC Flonase reached U.S. stores Feb. 3, a sign of additional product launches he expects the consumer health JV to do.

Glaxo Launches Flonase OTC, Banks On More Consumer Growth Drivers

CEO Andrew Witty says the consumer business GSK is forming through brand divestitures and its JV with Novartis is a part of “the company I've been trying to create for seven years.” GSK’s OTC Flonase reached U.S. stores Feb. 3, a sign of additional product launches he expects the consumer health JV to do.

B&L ReNu recall

Bausch & Lomb has initiated a permanent, worldwide recall of ReNu with MoistureLoc, the company announces May 15. Months of investigation have turned up no definitive answers as to why use of the product is causing Fusarium keratitis, a potentially blinding fungal infection, leading CEO Ron Zarrella to conclude that a 'perfect storm' occurs when the product usage encounters "certain environmental conditions, lens-wear care practices, and other factors." The CDC's Morbidity & Mortality Weekly Report issued May 19 affirms that the MoistureLoc formulation was the only ReNu product with a statistically significant association with reporsts of Rusarium Keratitis, the company notes. Sales of the product in 2005 totaled about $100 mil. The company is recommending its Renu Multiplus and ReNu Multi-Purpose as replacement solutions...

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS107248

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel